Availability of generic semaglutide removes barrier to affordable diabetes care, experts predict
· Medical Xpressby Elsevier
edited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.
The study in the Canadian Journal of Cardiology, provides key evidence regarding reimbursement and formulary decisions.
Generic semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has recently become available in Canada after regulatory exclusivity for semaglutide expired in Canada in January 2026—years earlier than expected in the U.S. and countries in Europe. Patients with type 2 diabetes and high cardiorenal risk are recommended to initiate a GLP-1RA and/or a sodium-glucose cotransporter-2 inhibitor (SGLT2i) according to Canadian and international guidelines.
The authors estimate that between 1.3 million and 2.1 million people living in Canada may meet the Canadian Cardiovascular Society criteria for patients with type 2 diabetes who are eligible to use GLP-1RAs or SGLT2is.
The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 billion to $5.31 billion at pre-generic 2025 semaglutide prices. In Canada, these costs are typically paid by provincial or private drug insurance plans but may be paid out of pocket when the drugs are not covered by a patient's insurance plan.
"The high cost of brand-name versions of these GLP-1RAs has been a significant barrier for patients and provincial insurers. Anticipated price reductions from the introduction of generic semaglutide could substantially alter the health economic value of programs aimed at initiating SGLT2i and GLP-1RA therapies for patients with type 2 diabetes and high cardiorenal risk," says the study's first author, Ethan McNally, BA, of McGill University School of Population and Global Health.
Using a health economic microsimulation model to project lifetime costs, quality-adjusted life years (QALYs), and the burden of cardiovascular and renal comorbidities for this high-risk patient group, the investigators examined how the cost-effectiveness of GLP-1RAs changes across a range of possible prices.
Key economic modeling outcomes
Guided by the commonly used threshold of $50,000 per QALY in Canada, the most important findings are as follows:
- At a 60% reduction from the 2025 pre-generic semaglutide price paid by the Quebec provincial drug plan, combined GLP-1RA and SGLT2i therapy may become the preferred strategy for this guideline-indicated cohort of patients, compared with either therapy alone or other standard-of-care therapies.
- At a 70% price reduction, GLP-1RA is predicted to be cost-effective compared with non-SGLT2i standard-of-care therapies (cost-effectiveness ratio [CER] of $22,700). SGLT2i is still predicted to be preferred over GLP-1RA alone, but dual therapy is predicted to be more cost-effective than either option alone (CER of $31,700 for dual therapy vs. SGLT2i alone).
Given the rapid growth in GLP-1RA use and high costs, this analysis may provide evidence for reimbursement and formulary decisions.
"Many provincial public drug plans limit GLP-1RA and SGLT2i reimbursement to patients who fail to meet glycemic targets. Multiple clinical guidelines now recommend these therapies for patients with type 2 diabetes at high cardiorenal risk, regardless of blood sugar levels. Given that our findings suggest that generic pricing may be cost-effective, payers could explore adjusting reimbursement criteria," notes lead investigator Abhinav Sharma, MD, Ph.D., DREAM-CV Lab, Research Institute, and Center for Outcome Research & Evaluation, McGill University Health Center.
These findings may generalize internationally once generic semaglutide becomes available in other countries.
Co-lead investigator Alton Russell, Ph.D., McGill University School of Population and Global Health, and Center for Outcome Research & Evaluation, McGill University Health Center, concludes, "Our results are encouraging and provide further economic justification for the use of these therapies among appropriate patients with type 2 diabetes in Canada, which will significantly improve quality of life, lower hospitalization costs, and ultimately protect patients from heart failure and kidney disease progression."
Publication details
Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes, Canadian Journal of Cardiology (2026). DOI: 10.1016/j.cjca.2026.05.013
Journal information: Canadian Journal of Cardiology
Key medical concepts
Clinical categories
EndocrinologyCardiologyClinical pharmacologyNephrology Provided by Elsevier Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Availability of generic semaglutide removes barrier to affordable diabetes care, experts predict (2026, July 22) retrieved 22 July 2026 from https://medicalxpress.com/news/2026-07-availability-generic-semaglutide-barrier-diabetes.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.